A Phase 3 interventional study of secukinumab and secukinumab in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Completed at 191 sites in 38 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one is the 2nd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 6 in phase 3, and was the 5th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 9 more countries
Ages 18–100
Novartis Pharmaceuticals · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in Korea, Republic of
Ages 6–100
Novartis Pharmaceuticals · Sites in Italy
Ages 18–100
By country, each count listing its studies:
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 702 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 545 across the 10 interventional studies, 125 across the 10 observational. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,718 studies on the registry; 221 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 438 (75%) have results posted.
9 of the studies in Hidradenitis Suppurativa by Novartis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
| NCT06517732Novartis PharmaceuticalsStudy to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation | 2026-12-31 |
| NCT07690319Novartis PharmaceuticalsA Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients | 2027-03-15 |
| NCT05921994Novartis PharmaceuticalsLong Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa. | 2027-03-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 21 studies in Hidradenitis Suppurativa by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).
This is a multicenter extension study to both core Phase III studies CAIN457M2301 and CAIN457M2302 (Core studies). This study contains a randomized withdrawal design, double blinded and placebo controlled up to Week 104 or loss of response. The subjects with HiSCR response after 52 weeks of treatment in the "Core studies" will be randomized at 2:1 ratio to either continue on one of the two Secukinumab dosing regimens assigned in "Core studies" for another 52 weeks or will be placed on placebo. The primary endpoint is loss of response (LOR) assessed during the 52-week treatment duration (up to Week 104). Subjects who attained LOR will be transferred to open-label treatment to continue until the end of the study. Subjects on placebo who did not reach LOR up to Week 104 will be offered to continue in the open-label treatment or discontinue the study. Thus for subjects who were HiSCR responders at Week 52 of "Core studies", the open label treatment duration will vary and start either from the time of LOR or from Week 104 dose and last until Week 260 followed by 8 weeks of a post treatment follow-up period to week 268.
Subjects who were HiSCR non-responders at the end of "Core studies" will be offered to continue in open-label treatment until Week 260.
Subjects who prematurely discontinue the study, or who complete the study will enter a post-treatment follow up period (8 weeks) The primary objective is to evaluate maintenance of HiSCR response at Week 104 in either continuous or interrupted therapy compared to placebo. Secondary objectives are to assess the long-term safety and tolerability evaluated by adverse events, abnormal laboratory values and vital signs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HiSCR responder at Week 52 in core trial, secukinumab 300mg every 2 weeks
Drug: secukinumab
HiSCR responder at Week 52 in core trial, secukinumab 300mg every 4 weeks
Drug: secukinumab
HiSCR responder at Week 52 in core trial, placebo to secukinumab 300mg every 2 weeks
Drug: secukinumab
HiSCR responder at Week 52 in core trial, placebo to secukinumab 300 mg every 4 weeks
Drug: secukinumab
non-responder at Week 52 in core trial treatment; secukinumab 300mg every 2 weeks
Drug: secukinumab
secukinumab 300mg every 2 weeks
Also known as: AIN457
secukinumab 300mg every 4 weeks
Also known as: AIN457
Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
Loss of response was defined as: * at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN. * at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks
Time frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders
The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand. * Day 1 = Date of 1st dose intake in the extension study. * Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval. * Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.
Time frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
Number of Participants With Treatment Emergent Adverse Events
To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)
Time frame: Up to 216 weeks: from randomization at the extension study (Week 52) up to Week 268. Study day is defined with respect to the core studies.
This study is conducted in 191 centers in 38 countries worldwide
| Milestone | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W |
|---|---|---|---|---|---|---|
| Started | 136 | 71 | 121 | 63 | 151 | 157 |
| Full analysis set of hiscr responders (fas-r) | 136 | 71 | 121 | 63 | 0 | 0 |
| Full analysis set of hiscr non-responders (fas-nr) | 0 | 0 | 0 | 0 | 151 | 156 |
| Safety set (saf) | 137 | 70 | 121 | 63 | 151 | 156 |
| Completed randomized withdrawal period - responders only | 127 | 64 | 114 | 62 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 136 | 71 | 121 | 63 | 151 | 157 |
| Withdrew: Ongoing at the time of the data cut-off date | 94 | 54 | 95 | 43 | 98 | 105 |
| Withdrew: Adverse event | 5 | 3 | 3 | 4 | 6 | 6 |
| Withdrew: Lack of efficacy | 5 | 1 | 3 | 2 | 18 | 7 |
| Withdrew: Lost to follow-up | 5 | 3 | 2 | 2 | 4 | 5 |
| Withdrew: Physician decision | 2 | 0 | 2 | 3 | 1 | 1 |
| Withdrew: Pregnancy | 3 | 0 | 3 | 0 | 1 | 2 |
| Withdrew: Withdrawal by subject | 22 | 10 | 12 | 8 | 23 | 31 |
| Withdrew: Technical problems | 0 | 0 | 1 | 1 | 0 | 0 |
Loss of response was defined as: * at least a 50% increase in abscess and/or nodules (AN) count compared to the average AN count from the 3 previous visits or at Week 52, whichever is lower and the increase was at least of 3 AN. * at least a 30% increase in AN compared to the average AN count from the 3 previous visits or Week 52, whichever is lower, with an increase of at least 2 AN and a further increase in the AN count of at least 2 AN at a re-assessment visit within 2-4 weeks
| Days | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W |
|---|---|---|---|---|---|---|
| Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) Responders | 283 (176 to —) | 239 (120 to —) | 365 (225 to —) | 171 (113 to 337) | — | — |
To assess the long-term safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa (HS)
Results for this outcome have not been posted.
The incidence rate of participants achieving Loss of Response (LOR) was based on the primary estimand. * Day 1 = Date of 1st dose intake in the extension study. * Subjects at risk = Subjects who did not have LOR and were not censored before or at the start of the specified time interval. * Incidence rate (%) = (number of subjects with LOR / number of subjects at risk) x 100.
| Percentage of participants | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W |
|---|---|---|---|---|---|---|
| Day 1 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
| 2 to 85 days | 26.9 | 23.9 | 24.2 | 30.2 | — | — |
| 86 to 141 days | 12.4 | 21.2 | 12.4 | 25.6 | — | — |
| 142 to 197 days | 8.4 | 9.8 | 6.6 | 9.4 | — | — |
| 198 to 253 days | 8.1 | 8.1 | 10.1 | 13.8 | — | — |
| 254 to 309 days | 10.4 | 18.2 | 6.5 | 4.0 | — | — |
| 310 to 351 days | 3.3 | 0.0 | 1.8 | 4.2 | — | — |
| 352 to 399 days | 5.4 | 0.0 | 5.4 | 9.1 | — | — |
Collected over From first dose of study treatment in the extension (Week 52) up to the cut-off date for the interim analysis (26-May-2023), approximately 3 years. Study day is defined with respect to the core studies.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AIN457 Q2WR-Q2W | 0/137 (0%) | 2/137 (1.5%) | 44/137 (32.1%) |
| AIN457 Q2WR-PBO | 0/70 (0%) | 4/70 (5.7%) | 23/70 (32.9%) |
| AIN457 Q4WR-Q4W | 0/121 (0%) | 5/121 (4.1%) | 46/121 (38%) |
| AIN457 Q4WR-PBO | 0/63 (0%) | 5/63 (7.9%) | 16/63 (25.4%) |
| Any AIN457 Q4W | 0/180 (0%) | 11/180 (6.1%) | 71/180 (39.4%) |
| Any AIN457 Q2W | 0/637 (0%) | 72/637 (11.3%) | 379/637 (59.5%) |
| Any AIN457 | 0/687 (0%) | 80/687 (11.6%) | 428/687 (62.3%) |
| AIN457 NR | 0/307 (0%) | 37/307 (12.1%) | 199/307 (64.8%) |
| Event | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | Any AIN457 Q4W | Any AIN457 Q2W | Any AIN457 | AIN457 NR |
|---|---|---|---|---|---|---|---|---|
| HidradenitisSkin and subcutaneous tissue disorders | 1/137 | 0/70 | 1/121 | 0/63 | 1/180 | 23/637 | 23/687 | 14/307 |
| Tongue coatedGastrointestinal disorders | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| DiverticulitisInfections and infestations | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| Oesophageal candidiasisInfections and infestations | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| Labia enlargedReproductive system and breast disorders | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| Perineal indurationReproductive system and breast disorders | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| Skin ulcerSkin and subcutaneous tissue disorders | 0/137 | 0/70 | 0/121 | 1/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| COVID-19Infections and infestations | 0/137 | 1/70 | 0/121 | 0/63 | 0/180 | 2/637 | 2/687 | 1/307 |
| GastroenteritisInfections and infestations | 0/137 | 1/70 | 0/121 | 0/63 | 0/180 | 1/637 | 1/687 | 1/307 |
| Groin abscessInfections and infestations | 0/137 | 1/70 | 0/121 | 0/63 | 0/180 | 0/637 | 0/687 | 0/307 |
| Event | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | Any AIN457 Q4W | Any AIN457 Q2W | Any AIN457 | AIN457 NR |
|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 11/137 | 6/70 | 11/121 | 7/63 | 19/180 | 128/637 | 147/687 | 58/307 |
| HidradenitisSkin and subcutaneous tissue disorders | 6/137 | 4/70 | 4/121 | 3/63 | 6/180 | 70/637 | 75/687 | 45/307 |
| NasopharyngitisInfections and infestations | 5/137 | 2/70 | 6/121 | 2/63 | 8/180 | 55/637 | 63/687 | 32/307 |
| HeadacheNervous system disorders | 3/137 | 0/70 | 4/121 | 0/63 | 9/180 | 32/637 | 41/687 | 15/307 |
| EczemaSkin and subcutaneous tissue disorders | 3/137 | 4/70 | 3/121 | 1/63 | 4/180 | 22/637 | 26/687 | 13/307 |
| C-reactive protein increasedInvestigations | 1/137 | 0/70 | 0/121 | 0/63 | 2/180 | 20/637 | 22/687 | 15/307 |
| Upper respiratory tract infectionInfections and infestations | 1/137 | 0/70 | 3/121 | 1/63 | 5/180 | 28/637 | 33/687 | 14/307 |
| BronchitisInfections and infestations | 2/137 | 0/70 | 0/121 | 2/63 | 1/180 | 28/637 | 29/687 | 14/307 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/137 | 0/70 | 3/121 | 0/63 | 3/180 | 20/637 | 23/687 | 14/307 |
| AcneSkin and subcutaneous tissue disorders | 0/137 | 1/70 | 2/121 | 0/63 | 2/180 | 20/637 | 22/687 | 14/307 |
| Age, Continuous(Years) | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W | Total |
|---|---|---|---|---|---|---|---|
| Mean | 35.7 ± 11.26 | 34.8 ± 10.55 | 35.4 ± 12.59 | 36.0 ± 11.32 | 37.3 ± 11.00 | 37.1 ± 11.13 | 36.1 ± 11.31 |
| Sex: Female, Male(Participants) | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W | Total |
|---|---|---|---|---|---|---|---|
| Female | 73 | 38 | 64 | 28 | 91 | 78 | 372 |
| Male | 63 | 33 | 57 | 35 | 60 | 79 | 327 |
| Race/Ethnicity, Customized(Participants) | AIN457 Q2WR-Q2W | AIN457 Q2WR-PBO | AIN457 Q4WR-Q4W | AIN457 Q4WR-PBO | AIN457 Q2WNR-Q2W | AIN457 Q4WNR-Q2W | Total |
|---|---|---|---|---|---|---|---|
| White | 113 | 51 | 90 | 48 | 115 | 111 | 528 |
| Black or African American | 8 | 6 | 11 | 7 | 6 | 14 | 52 |
| Asian | 12 | 11 | 13 | 6 | 24 | 28 | 94 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| American Indian or Alaska Native | 2 | 2 | 5 | 2 | 3 | 3 | 17 |
| Multiple | 1 | 1 | 2 | 0 | 2 | 1 | 7 |
Showing the first 100 of 191 sites across 38 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2020 to primary completion in May 2023, 38 months.
Results were first posted in Jun 2024, 1 year after primary completion.
Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 38 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab